Although no clinical CAR T-cell trials for hepatocellular cancer have been completed to date, some preclinical and clinical evidence suggests a potent antitumor activity for therapies targeting CEA, MUC-1, and GPC-3 antigens [84,85]. Here, GPC3 is linked to hepatocellular carcinoma.